Michael B. Maris

Victor Babeș University of Medicine and Pharmacy Timișoara — Romania

Medicine · Health Sciences

60h-index16.7kcitations244works4.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(107), Acute Myeloid Leukemia Research(58), Chronic Lymphocytic Leukemia Research(36), Acute Lymphoblastic Leukemia research(34), Immune Cell Function and Interaction(30)

Publications244 total

The place of advanced machine learning techniques in building pancreatic adenocarcinoma survival and recurrence prognosis models
Frontiers in Oncology·2025Open Access
A dose optimization phase 1b/2 study evaluating mipletamig (formerly APVO436), a novel bispecific CD123 x CD3 ADAPTIRÒ molecule in combination therapy for the treatment of frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy
Blood·2025Open Access
1306eP Delayed engraftment in autologous stem cell transplant patients receiving olanzapine
Annals of Oncology·2025
ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia
Blood·2025· 6 cited
Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion Before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma
Transplantation and Cellular Therapy·2025· 3 cited
Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network
Blood Advances·2024· 14 citedOpen Access
Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting
Clinical Hematology International·2024· 1 citedOpen Access
OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL
Blood Advances·2024· 14 citedOpen Access
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study
Targeted Oncology·2024· 9 citedOpen Access
Outpatient Administration of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Non-Hodgkin Lymphoma (NHL), in a Large Multi-Center Network
Transplantation and Cellular Therapy·2024
Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy
Transplantation and Cellular Therapy·2024· 1 cited
EE116 Quantifying the Future Impact of Chronic Kidney Disease Screening Programs in Belgium
Value in Health·2023
EPH205 Inside CKD: Predicting the Clinical and Economic Burden of Chronic Kidney Disease in Belgium
Value in Health·2023Open Access
Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy
Blood·2023· 2 citedOpen Access
CT-045 Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Clinical Lymphoma Myeloma & Leukemia·2023· 1 citedOpen Access
POSTER: CT-045 Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Clinical Lymphoma Myeloma & Leukemia·2023
Cardio–Renal–Metabolic Syndrome: Clinical Features and Dapagliflozin Eligibility in a Real-World Heart Failure Cohort
ESC Heart Failure·2023· 12 citedOpen Access
Data from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
2023Open Access
Supplementary Data from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
2023Open Access
Data from A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
2023Open Access
page 1 of 13Next →

Frequent Co-authors

Brenda M. Sandmaier(38), David G. Maloney(38), Rainer Storb(37), Barry E. Storer(27), Thomas R. Chauncey(24), Mohamed L. Sorror(18), Michael A. Pulsipher(14), Peter A. McSweeney(13), Benedetto Bruno(13), Richard T. Maziarz(12), Dietger Niederwieser(11), Karl G. Blume(11), Edward Agura(11), Amelia Langston(10), H. Joachim Deeg(8), Paul J. Martin(7), Mary E.D. Flowers(7), Judith A. Shizuru(7), Thoralf Lange(7), Ann E. Woolfrey(7)